These innovative medications , Retatrutide, represent a groundbreaking advancement in addressing obesity and potentially associated conditions . They all are categorized as GLP-1 receptor agonists , meaning https://adrianawdbi452873.blogars.com/39866966/semaglutide-a-comprehensive-exploration-into-metabolic-agents